Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TiPAP for PTSD
NCT07737054Phase 1Recruiting
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of psilocybin in post-traumatic stress disorder (PTSD), sponsored by Tel Aviv Sourasky Medical Center. Primary endpoints: Number of Participants With One or More Treatment-Emergent Adverse Events and Number of Participants Completing the Full Therapeutic Intervention. Started Jul 2025; status: recruiting.
02
Drugs
psilocybin
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT07737054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07737054.